Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Key Drivers
3.1.1. Growing Nash Affected Population
3.1.2. Surging Prevalence Of Obesity And Diabetes
3.1.3. Increasing Occurrence Of Chronic Diseases
3.1.4. Surging Awareness Of Non-Alcoholic Fatty Liver Disease
3.2. Key Restraints
3.2.1. Side-Effects And Risks Associated With Nash Therapeutics
3.2.2. Lack Of Specialized Diagnostic Test For Non-Alcoholic Fatty Liver Disease (Nafld)

4. Key Analytics
4.1. Porter’S Five Forces Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’S Power
4.1.4. Supplier’S Power
4.1.5. Competitive Rivalry
4.2. Impact Of Covid-19 On Non-Alcoholic Steatohepatitis (Nash) Biomarker Market
4.3. Opportunity Matrix
4.4. Vendor Landscape
4.5. Key Investment Insights

5. Market By Type
5.1. Serum Biomarker
5.2. Hepatic Fibrosis Biomarker
5.3. Apoptosis Biomarker
5.4. Oxidative Stress Biomarker
5.5. Other Types

6. Market By End-User
6.1. Pharma & Cro Industry
6.2. Diagnostic Lab
6.3. Academic Research Key
6.4. Hospital

7. Geographical Analysis
7.1. North America
7.1.1. Market Size & Estimates
7.1.2. Key Growth Enablers
7.1.3. Key Challenges
7.1.4. Key Players
7.1.5. Country Analysis
7.1.5.1. The United States
7.1.5.2. Canada
7.2. Europe
7.2.1. Market Size & Estimates
7.2.2. Key Growth Enablers
7.2.3. Key Challenges
7.2.4. Key Players
7.2.5. Country Analysis
7.2.5.1. Germany
7.2.5.2. France
7.2.5.3. The United Kingdom
7.2.5.4. Italy
7.2.5.5. Russia
7.2.5.6. Belgium
7.2.5.7. Poland
7.2.5.8. Rest Of Europe
7.3. Asia Pacific
7.3.1. Market Size & Estimates
7.3.2. Key Growth Enablers
7.3.3. Key Challenges
7.3.4. Key Players
7.3.5. Country Analysis
7.3.5.1. China
7.3.5.2. Japan
7.3.5.3. Australia & New Zealand
7.3.5.4. India
7.3.5.5. South Korea
7.3.5.6. Thailand
7.3.5.7. Indonesia
7.3.5.8. Vietnam
7.3.5.9. Rest Of Asia Pacific
7.4. Rest Of World
7.4.1. Market Size & Estimates
7.4.2. Key Growth Enablers
7.4.3. Key Challenge
7.4.4. Key Players
7.4.5. Regional Analysis
7.4.5.1. Latin America
7.4.5.2. Middle East & Africa

8. Competitive Landscape
8.1. Key Strategic Developments
8.1.1. Merger & Acquisitions
8.1.2. Product Launch & Developments
8.1.3. Partnership, Contract/Agreement & Collaboration
8.1.4. Business Expansion/ Approval/ Announcement
8.2. Company Profile
8.2.1. Allergan Plc (Acquired By Abbvie)
8.2.2. Astrazeneca
8.2.3. Bristol -Myers Squibb Company
8.2.4. Genfit Sa
8.2.5. Gilead Sciences, Inc
8.2.6. Madrigal Pharmaceuticals
8.2.7. Merck & Co
8.2.8. Novartis Ag
8.2.9. Novo Nordisk
8.2.10. Pfizer Inc
8.2.11. Siemens Healthineers
8.2.12. Viking Therapeutics
8.2.13. Zydus Cadila



List of Figures


Figure 1: Porter’S Five Force Analysis
Figure 2: Opportunity Matrix
Figure 3: Vendor Landscape
Figure 4: Key Investment Insights
Figure 5: Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Type, In 2020
Figure 6: Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Serum Biomarker, 2021-2028 (In $ Million)
Figure 7: Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Hepatic Fibrosis Biomarker, 2021-2028 (In $ Million)
Figure 8: Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Apoptosis Biomarker, 2021-2028 (In $ Million)
Figure 9: Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Oxidative Stress Biomarker, 2021-2028 (In $ Million)
Figure 10: Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Other Types, 2021-2028 (In $ Million)
Figure 11: Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By End-User, In 2020
Figure 12: Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Pharma & Cro Industry, 2021-2028 (In $ Million)
Figure 13: Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Diagnostic Lab, 2021-2028 (In $ Million)
Figure 14: Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Academic Research Key, 2021-2028 (In $ Million)
Figure 15: Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Hospital, 2021-2028 (In $ Million)
Figure 16: North America Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, Country Outlook, 2020 & 2028 (In %)
Figure 17: United States Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 18: Canada Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 19: Europe Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, Country Outlook, 2020 & 2028 (In %)
Figure 20: Germany Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 21: France Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 22: United Kingdom Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 23: Italy Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 24: Russia Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 25: Belgium Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 26: Poland Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 27: Rest Of Europe Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 28: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, Country Outlook, 2020 & 2028 (In %)
Figure 29: China Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 30: Japan Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 31: Australia & New Zealand Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 32: India Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 33: South Korea Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 34: Thailand Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 35: Indonesia Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 36: Vietnam Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 37: Rest Of Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 38: Rest Of World Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, Regional Outlook, 2020 & 2028 (In %)
Figure 39: Latin America Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 40: Middle East & Africa Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)


List of Tables


List of Tables


TABLE 1: MARKET SNAPSHOT - NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER
TABLE 2: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 3: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 4: GLOBAL SERUM BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 5: GLOBAL SERUM BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 6: GLOBAL HEPATIC FIBROSIS BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 7: GLOBAL HEPATIC FIBROSIS BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 8: GLOBAL APOPTOSIS BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 9: GLOBAL APOPTOSIS BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 10: GLOBAL OXIDATIVE STRESS BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 11: GLOBAL OXIDATIVE STRESS BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 12: GLOBAL OTHER TYPES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 13: GLOBAL OTHER TYPES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 14: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 15: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 16: GLOBAL PHARMA & CRO INDUSTRY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 17: GLOBAL PHARMA & CRO INDUSTRY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 18: GLOBAL DIAGNOSTIC LAB MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 19: GLOBAL DIAGNOSTIC LAB MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 20: GLOBAL ACADEMIC RESEARCH KEY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 21: GLOBAL ACADEMIC RESEARCH KEY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 22: GLOBAL HOSPITAL MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 23: GLOBAL HOSPITAL MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 24: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 25: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 26: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 27: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 28: LEADING PLAYERS OPERATING IN NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
TABLE 29: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 30: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 31: LEADING PLAYERS OPERATING IN EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
TABLE 32: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 33: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 34: LEADING PLAYERS OPERATING IN ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
TABLE 35: REST OF WORLD NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 36: REST OF WORLD NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 37: LEADING PLAYERS OPERATING IN REST OF WORLD NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET